IL239714A0 - Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseases - Google Patents

Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseases

Info

Publication number
IL239714A0
IL239714A0 IL239714A IL23971415A IL239714A0 IL 239714 A0 IL239714 A0 IL 239714A0 IL 239714 A IL239714 A IL 239714A IL 23971415 A IL23971415 A IL 23971415A IL 239714 A0 IL239714 A0 IL 239714A0
Authority
IL
Israel
Prior art keywords
metformin
diabetes
disorders
combinations
treatment
Prior art date
Application number
IL239714A
Other languages
English (en)
Hebrew (he)
Original Assignee
Vtv Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50030537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL239714(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vtv Therapeutics Llc filed Critical Vtv Therapeutics Llc
Publication of IL239714A0 publication Critical patent/IL239714A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL239714A 2013-01-17 2015-06-30 Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseases IL239714A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361753567P 2013-01-17 2013-01-17
PCT/US2014/011394 WO2014113357A1 (en) 2013-01-17 2014-01-14 Combinations of a glp1r agonist and metformin and use thereof for the treatment of type 2 diabetes and other disorders

Publications (1)

Publication Number Publication Date
IL239714A0 true IL239714A0 (en) 2015-08-31

Family

ID=50030537

Family Applications (1)

Application Number Title Priority Date Filing Date
IL239714A IL239714A0 (en) 2013-01-17 2015-06-30 Combination of glp1r agonist and metformin and its use in the treatment of type 2 diabetes and other diseases

Country Status (13)

Country Link
US (1) US20150313908A1 (enExample)
EP (1) EP2945618B1 (enExample)
JP (1) JP6445459B2 (enExample)
KR (1) KR102165434B1 (enExample)
CN (1) CN104968341B (enExample)
AU (1) AU2014207748B2 (enExample)
CA (1) CA2896308C (enExample)
EA (1) EA201591123A1 (enExample)
ES (1) ES2687083T3 (enExample)
IL (1) IL239714A0 (enExample)
MX (1) MX366685B (enExample)
SG (2) SG10201704716XA (enExample)
WO (1) WO2014113357A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684793A1 (en) 2017-09-22 2020-07-29 Regeneron Pharmaceuticals, Inc. Glucagon-like peptide 1 receptor agonists and uses thereof
WO2019217165A1 (en) * 2018-05-08 2019-11-14 Vtv Therapeutics Llc Therapeutic uses of glp1r agonists
EP4130005A4 (en) * 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
CN115315426B (zh) * 2020-04-01 2023-12-12 杭州中美华东制药有限公司 Glp-1受体激动剂游离碱的药学上可接受的酸式盐及其制备方法
US12582651B2 (en) * 2020-12-31 2026-03-24 Dong Kook Pharm. Co., Ltd. Pharmaceutical composition comprising tadalafil or pharmaceutically acceptable salt thereof and dutasteride or pharmaceutically acceptable salt thereof exhibiting novel dissolution rate
JP2025532651A (ja) 2022-09-21 2025-10-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 肥満、糖尿病および肝機能障害を処置する方法
WO2025158275A1 (en) 2024-01-24 2025-07-31 Pfizer Inc. Combination therapy using glucose-dependent insulinotropic polypeptide receptor antagonist compounds and glp-1 receptor agonist compounds
US20260199503A1 (en) 2025-01-10 2026-07-16 Regeneron Pharmaceuticals, Inc. Glp1r agonist-tethered gdf8 antibody conjugates and uses thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4080472A (en) 1974-03-22 1978-03-21 Societe D'etudes Et D'exploitation De Marques Et Brevets S.E.M.S. Metformin 2-(p-chlorophenoxy)-2-methylpropionate
AU2006311601A1 (en) * 2005-11-07 2007-05-18 Elixir Pharmaceuticals, Inc. Combinations of metformin and meglitinide
EA018225B1 (ru) * 2008-03-07 2013-06-28 Транстек Фарма, Инк. Соединения оксадиазоантрацена для лечения диабета
MX2011010347A (es) * 2009-03-30 2011-11-29 Transtech Pharma Inc Derivados sustituidos de azoantraceno, composiciones farmaceuticas y metodos de uso de los mismos.
WO2011031620A1 (en) 2009-09-11 2011-03-17 Transtech Pharma, Inc. Solid compositions comprising an oxadiazoanthracene compound and methods of making and using the same
JP5832439B2 (ja) * 2009-11-13 2015-12-16 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Glp−1アゴニスト、インスリン及びメチオニンを含む薬学的組成物
US20110118180A1 (en) * 2009-11-13 2011-05-19 Sanofi-Aventis Deutschland Gmbh Method of treatment of diabetes type 2 comprising add-on therapy to metformin
US20130040878A1 (en) * 2011-05-13 2013-02-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in the treatment of diabetes type 2 patients

Also Published As

Publication number Publication date
AU2014207748A1 (en) 2015-07-09
MX2015008555A (es) 2016-01-22
ES2687083T3 (es) 2018-10-23
EP2945618B1 (en) 2018-06-13
SG11201504778UA (en) 2015-07-30
EP2945618A1 (en) 2015-11-25
KR102165434B1 (ko) 2020-10-14
AU2014207748B2 (en) 2018-10-11
MX366685B (es) 2019-07-19
WO2014113357A1 (en) 2014-07-24
JP6445459B2 (ja) 2018-12-26
EA201591123A1 (ru) 2015-11-30
KR20150104572A (ko) 2015-09-15
HK1210424A1 (en) 2016-04-22
CA2896308A1 (en) 2014-07-24
SG10201704716XA (en) 2017-07-28
US20150313908A1 (en) 2015-11-05
CN104968341B (zh) 2020-06-09
JP2016505039A (ja) 2016-02-18
CA2896308C (en) 2021-11-09
CN104968341A (zh) 2015-10-07

Similar Documents

Publication Publication Date Title
IL283979B (en) 3,1-thiazol-2-yl converted benzamides
SG10201704716XA (en) Combinations Of A GLP1R Agonist And Metformin And Use Thereof For The Treatment Of Type 2 Diabetes And Other Disorders
IL245408A0 (en) Converted benzamides for the treatment of arthropods
IL240285A0 (en) Biomarkers for type ii diabetes and their uses
PT2919796T (pt) Utilização de akkermansia para o tratamento de distúrbios metabólicos
PT3811943T (pt) Composto para uso no tratamento de distúrbios oculares
PL3046470T3 (pl) Diagnozowanie i leczenie zaburzeń ruchu
IL239957A0 (en) Assessment, testing and treatment of pkal mediated disorders
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
IL238027A0 (en) 2-phenyl-5-heterocyclyl-tetrahydro-h2-pyran-3-amine compounds for use in the treatment of diabetes and related disorders
IL243572A0 (en) Drug combination for the treatment of melanoma
GB201314753D0 (en) Wrist worn device
GB2519982B (en) Fungicidal composition and the use thereof
IL242437B (en) Compound 9, 5-dimethyl-9-hydroxy-decan-4-al, its use and its preparation process
PL3041441T3 (pl) Orteza ręki do podtrzymywania kciuka szczególnie w przypadku rizartrozy
PL3160464T3 (pl) 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
IL241474B (en) A device with joints for the wrist
SI3074033T1 (sl) Spojine za zdravljenje debelosti in postopki njihove uporabe
GB201320506D0 (en) Cyclic amino compounds for the use in the treatment of cardiac disorders
EP3713604C0 (de) Verbindung zur anwendung bei der steigerung von mentaler leistungsfähigkeit
GB201800645D0 (en) Monitoring medication consumption
GB201314183D0 (en) Status of type 2 diabetes
GB201304197D0 (en) Thumb pad embodiments
TWM476976U (en) Wrist pad
TWM476582U (en) Watch type stethoscope device